Telehealth Mitigated Negative Impact on Urologic Oncologic Appointments During COVID-19 Pandemic


Research presented at the 21st Annual Meeting of the Society of Urologic Oncology found organized telehealth systems effectively lessened the impact of the coronavirus disease 2019 pandemic on appointment cancellations.

During the coronavirus disease 2019 (COVID-19) pandemic, an organized telehealth program helped to mitigate the negative impact of the pandemic on outpatient urologic-oncologic visits, according to data published in a poster at the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

While the pandemic caused a sharp increase in outpatient visit cancellations, the rapid adoption of telehealth pathways helped to reverse the downswing trend in outpatient and increased cancellations.

“When comparing between 2019 and 2020, our data show decreases in new patient appointment rates for certain urologic cancers (renal and testicular) and comparable rates for others (prostate and bladder),” wrote the researchers. “These differences are likely attributed to varying requirements for visits for different oncologic conditions (physical exam, in-office procedure). The implementation of telehealth helped reverse the initial urologic-oncologic outpatient volume decline at our institution.”

A significant decrease in urologic-oncologic outpatient visits (n=1381) was seen in 2020 during weeks 1-3 of the study (average weekly percentage change [AWPC]: -28.1%; p<0.001), while weeks 1-4 saw a significant increase in oncology telehealth appointments (AWPC: +391.2%; p<.001). More, overall appointments increased significantly from week 6, when the overall appointment trend inflected, to week 13 (AWPC: +7.3%; p<0.001).

In 2019, urologic-oncologic appointments (n=2100) saw no significant changes for overall, new and established patient visits (AWPC: -0.2%, -1.9%, +0.5%; all p>0.2). Meanwhile in 2020, new patient oncologic visits saw a sharp decrease while established patient oncologic visits sharply increased (AWPC: -3.2% vs. +0.8%; p<0.001). Further, cancellations significantly increased in the first 3 weeks of 2020 that were studied (AWPC: +54.9%; p<0.001) but stabilized following that period (AWPC: +5.2; p>0.1).

Broken down by cancer type, patients evaluated via telehealth were 58.2% for prostate cancer, 51.7% for renal cancer, 54.2% for testicular cancer and 42.1% for bladder cancer. When comparing new appointment rates for 2019 and 2020, the percentages were 22.7% vs. 21.4% for prostate cancer, 19.2% vs. 12.3% for renal cancer, 13.7% vs. 13.8% for bladder cancer and 26.5% vs. 14.1% for testicular cancer, respectively.

“Our data show significant contrasting trends for overall new and established patient oncologic visits,” wrote the researchers. “We see differing rates of telehealth usage for different urologic-oncologic conditions.”

The researchers performed a retrospective analysis of the urologic-oncologic visits performed at a tertiary referral center from March 1 to June 1, 2020. Then, they implemented a join-point regression model to examine statistically significant trends of patient visits over time. The team used AWPC to summarize the linear trends identified.

Moving forward, the researchers stress that further research is necessary to “clarify clinical implications and potential deficits” in patient care during the COVID-19 pandemic given the appointment and telehealth utilization trends identified.

“With its rapid implementation, it is important to study whether telehealth adequately supplemented in-person medical appointments,” wrote the researchers. “Additionally, it is important to identify potentially differential impacts on frequently encountered urologic oncologic conditions.”


Sanford D, Reddy SS, Park D, et al. Join-Point Regression Modeling of Trends in Urologic Oncologic Outpatient Appointments and Telehealth Usage at a Tertiary Referral Center during the COVID-19 Pandemic. Presented at: 21st Annual Meeting of the Society of Urologic Oncology; December 3, 2020. Poster #67.

Related Videos
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Adam J. Gadzinski, MD, MS
Related Content